QT-Prolongation in Lung Transplantation

Primary endpoint:

• prevalence of significant QTc-interval prolongation (500 msec or above) after lung transplantation

Key secondary endpoint(s):

• prevalence of any QTc-interval prolongation (>440 msec ) after lung transplantation
• prevalence of PQ prolongation (200 msec sec or above) after lung transplantation
• prevalence of QRS prolongation (120 msec or above) after lung transplantation
• prevalence of QTc-prolonging drugs in drug regimen before and after lung transplantation
• influence of long-term neo-macrolide (e.g. azithromycin) on QTc interval after lung transplantation
• intra-individual difference of QTc interval before and after lung transplantation
• incidence of any QTc-interval prolongation(>440 msec ) after lung transplantation
• incidence of any QTc-interval prolongation (>440 msec or increase by 50msec or above) after initiation of new QTc prolonging drugs (especially neo-macrolides)
• reversal of QTc-interval prolongation (440 msec or lower or decrease by 50msec or above) after stopping any QTc prolonging drug
• Assessment of safety:
• Incidence of new onset heart rhythm disorder during 6 months of follow-up